(Q50586139)

English

A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.

scientific article published in January 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

author name string

Z M Younossi

1

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

K D Mullen

2

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

W Zakko

3

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

S Hodnick

4

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

E Brand

5

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

D S Barnes

6

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

W D Carey

7

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

A C McCullough

8

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

N Boparai

10

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

T Gramlich

11

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

publication date

1 January 2001

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

Journal of Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

34

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

1

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

128-133

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C: an update on the silent epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C: the clinical spectrum of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The long-term pathological evolution of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Histopathology of Hepatitis C Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment strategies for hepatitis C: making the best of limited options

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900003-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8278(00)00003-9

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 March 2018

http://europepmc.org/abstract/MED/11211889

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50586139&oldid=1540628584"